Works matching AU Desar, I. M. E.

Results: 8

Double burden: financial toxicity in patients with advanced soft tissue sarcoma at the start of first-line palliative chemotherapy: baseline data from the HOLISTIC study.
Published in:
Supportive Care in Cancer, 2025, v. 33, n. 3, p. 1, doi. 10.1007/s00520-025-09248-5
By:
- Roets, E.;
- Younger, E.;
- Jones, R. L.;
- Hollander, D.den;
- Desar, I. M. E.;
- Young, R. J.;
- Oosten, A. W.;
- de Haan, J. J.;
- Gelderblom, H.;
- Steeghs, N.;
- van der Graaf, W. T. A.;
- Husson, O.
Publication type:
Article
Functional MRI techniques demonstrate early vascular changes in renal cell cancer patients treated with sunitinib: a pilot study.
Published in:
2011
By:
- Desar, I. M. E.;
- ter Voert, E. G. W.;
- Hambrock, Th.;
- van Asten, J. J. A.;
- van Spronsen, D. J.;
- Mulders, P. F. A.;
- Heerschap, A.;
- van der Graaf, W. T. A.;
- van Laarhoven, H. W. M.;
- van Herpen, C. M. L.
Publication type:
journal article
Real-world data on the management of pazopanib-induced liver toxicity in routine care of renal cell cancer and soft tissue sarcoma patients.
Published in:
Cancer Chemotherapy & Pharmacology, 2024, v. 93, n. 4, p. 353, doi. 10.1007/s00280-023-04615-7
By:
- Westerdijk, K.;
- Krens, S. D.;
- Steeghs, N.;
- van der Graaf, W. T. A.;
- Tjwa, E. T. T. L.;
- Westdorp, H.;
- Desar, I. M. E.;
- van Erp, N. P.
Publication type:
Article
Predictive factors for toxicity and survival of second-line sunitinib in advanced gastrointestinal stromal tumours (GIST).
Published in:
Acta Oncologica, 2019, v. 58, n. 11, p. 1648, doi. 10.1080/0284186X.2019.1637017
By:
- Den Hollander, D.;
- Van der Graaf, W. T. A.;
- Desar, I. M. E.;
- Le Cesne, A.
Publication type:
Article
Capecitabine, irinotecan (CAPIRI) and sunitinib in metastatic colorectal cancer.
Published in:
2013
By:
- Boers-Sonderen, M. J.;
- Desar, I. M. E.;
- Koopman, M.;
- Punt, C. J.;
- van Herpen, C. M. L.
Publication type:
Letter
Analysis of PD-1, PD-L1, and T-cell infiltration in angiosarcoma pathogenetic subgroups.
Published in:
Immunologic Research, 2022, v. 70, n. 2, p. 256, doi. 10.1007/s12026-021-09259-4
By:
- Tomassen, T.;
- Weidema, M. E.;
- Hillebrandt-Roeffen, M. H. S.;
- van der Horst, C.;
- Desar, I. M. E.;
- Flucke, U. E.;
- Versleijen-Jonkers, Yvonne M. H.
Publication type:
Article
A phase I dose-escalation study to evaluate safety and tolerability of sorafenib combined with sirolimus in patients with advanced solid cancer.
Published in:
2010
By:
- Desar, I. M. E.;
- Timmer-Bonte, J. N. H.;
- Burger, D. M.;
- van der Graaf, W. T. A.;
- van Herpen, C. M. L.
Publication type:
journal article
Serum bactericidal activity against Helicobacter pylori in patients with hypogammaglobulinaemia.
Published in:
Clinical & Experimental Immunology, 2009, v. 156, n. 3, p. 434, doi. 10.1111/j.1365-2249.2009.03909.x
By:
- Desar, I. M. E.;
- van Deuren, M.;
- Sprong, T.;
- Jansen, J. B. M. J.;
- Namavar, F.;
- Vandenbroucke-Grauls, C. M.;
- van der Meer, J. W. M.
Publication type:
Article